StockNews.AI
ZYXI
StockNews.AI
155 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zynex, Inc. - ZYXI

1. Pomerantz LLP investigates claims of securities fraud against Zynex, Inc. 2. Zynex reported a revenue shortfall due to delayed payments from some payers. 3. Tricare suspended payments, representing 20-25% of Zynex's annual revenue. 4. Zynex's stock fell 51.3% to $3.41 after revealing financial results.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The investigation and revenue shortfall indicate potential fraud, depressing investor confidence. Historical instances show similar investigations can lead to prolonged stock price declines.

How important is it?

The article discusses a significant downturn in Zynex's financial condition linked to potential fraud, crucial for investor decisions.

Why Short Term?

Immediate stock price reaction is negative due to investigation news, but long-term effects depend on resolution. Past cases of sudden price drops have lingered for years when fraud was suspected.

Related Companies

TRICAAPLMSFT
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zynex, Inc. ("Zynex" or the "Company") (NASDAQ: ZYXI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Zynex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On March 11, 2025, Zynex reported its fourth quarter and full year 2024 financial results, revealing a revenue "shortfall" in the quarter "due to slower than normal payments from certain payers." Zynex also revealed that Tricare, the healthcare program for uniformed service members that "currently represents approximately 20-25% of [the Company's] annual revenue", "has temporarily suspended payments as they review prior claims."  On this news, Zynex's stock price fell $3.59 per share, or 51.3%, to close at $3.41 per share on March 12, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLP[email protected]646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News